hotspot -WSS

hotspot

author：focus 2025-09-29 21:21:01 - browse：9

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large trial of its gene therapy for Duchenne muscular dystrophy marked a clear medical breakthrough. “A massive win,” he told investors, that could lead to its approval for all patients with the fatal muscle-wasting disease regardless of age.

And yet the rest of the Duchenne community was more cautious in its enthusiasm. The study — the most rigorous test to date of a technology 30 years in the making — had technically failed, as so many had before it.

“It’s extremely frustrating,” said John Brandsema, a pediatric neurologist at Children’s Hospital of Philadelphia who worked on the study. “When you spend decades trying to bring therapies into the clinic for something so severe and just keep missing over and over again.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： FDA approves updated Covid vaccines

focus

leisure time

WSS

In search for therapies for solid tumors, companies turn to claudin

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

FDA approves updated Covid vaccines

RSV vaccines may be linked to small increased risk of developing GBS

Acelyrin, a rare IPO success, stumbles in its first big test

Popular nasal decongestant doesn't actually relieve congestion

leisure time

hotspot

Wikipedia

Continuity nursing helped my family in our darkest PICU moments

An inside look at PIPEs, biotech's buzzy new financing tool

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

How medical schools plan to diversify without affirmative action

United colonoscopy coverage change 'may cost lives,' doctors say

FDA does about

BioMarin wins approval for gene therapy to treat hemophilia A

FDA does about

Psychedelics group wrestles with new pharma identity

WATCH: Why do bright lights make us see spots?

Wikipedia

IRA could hurt research into orphan drugs for rare diseases

Acelyrin, a rare IPO success, stumbles in its first big test

How to address the problem of discarded donor organs

Generate Biomedicines machine learning biotech raises $273M

Medical device lobby: We're tired of waiting on Medicare coverage

New Covid vaccine is recommended for everyone 6 months or older

focus

focus

leisure time

focus